目的: 探讨糖类抗原125(CA125)、前白蛋白(PA)、胆碱酯酶(CHE)和红细胞分布宽度(RDW)评价肝硬化患者肝功能的价值。方法: 随机选取2023年6月至2024年10月于包头市中心医院消化科初诊初治肝硬化患者80例,根据肝硬化分期将研究组分为代偿期组(25例),失代偿期组(55例),对照组选取体检中心体检者的血清标本100例,比较不同分组之间的CA125、PA、CHE和RDW,采用ROC曲线下面积(AUC)评估CA125、PA、CHE和RDW单项或联合检测对肝硬化患者肝功能的评估价值;采用Spearman相关性分析法分析CA125、PA、CHE以及RDW水平与疾病严重程度相关性。结果: 研究组血清CA125、RDW水平高于对照组,而PA、CHE水平较对照组下降,差异具有统计学意义(P＜0.05);ROC曲线结果显示,血清CA125、PA、CHE以及RDW联合检测的AUC值为0.96,高于其他单项检测的AUC;相关性分析显示,联合检测与疾病严重程度的相关性更强。结论: 不同时期肝硬化患者的CA125、PA、CHE和RDW水平存在明显差异,联合检测对评估肝硬化患者肝功能具有更高价值。
Objective: To investigate the value of CA125, PA, CHE and RDW in evaluating liver function in patients with liver cirrhosis. Methods: A total of 80 patients with liver cirrhosis who were first diagnosed and treated in the Department of Gastroenterology of Baotou Central Hospital from June 2023 to October 2024 were randomly selected. According to the period of liver cirrhosis, they were divided into compensatory group (25 patients) and decompensated group (55 patients). The serum samples of 100 patients with normal results were selected in the control group. The CA125, prealbumin (PA), cholinesterase (CHE) and red blood cell distribution width (RDW) were compared between the study group and the control group. The area under the ROC curve (AUC) was used to evaluate the value of single or combined detection of CA125, PA, CHE and RDW in evaluating liver function in patients with cirrhosis. Spearman correlation analysis was used to analyze the correlation between CA125, PA, CHE and RDW levels and disease severity. Results: The levels of serum CA125 and RDW in the study group were higher than those in the control group, while the levels of PA and CHE were lower than those in the control group, and the differences were statistically significant (P＜0.05). ROC curve results showed that the AUC value of combined detection of serum CA125, PA, CHE and RDW was 0.96, which was higher than that of other single detections. Correlation analysis showed that the correlation between combined detection and disease severity was stronger (r=0.87) (P＜0.05). Conclusion: There are significant differences in CA125, PA, CHE and RDW levels in patients with cirrhosis at different stages. Combined detection has a higher value in evaluating liver function in patients with cirrhosis.
[1] 周红宇, 周昌文.血清球蛋白、胆碱酯酶及其比值与肝硬化肝脏储备功能评估的研究进展[J].临床消化病杂志, 2019, 31(4):267-270.
[2] 周翠微.肝硬化失代偿期患者的护理研究进展[J].中国当代医药, 2023, 30(14):42-45, 49.
[3] 杨连粤, 白雪莉.肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J].中国实用外科杂志, 2019, 39(12):1241-1247.
[4] 乐滢玉, 张荣臻, 肖伟松, 等.肝性脑病发病机制的研究进展[J].中西医结合肝病杂志, 2022, 32(5):468-472.
[5] 陈乾, 林慧敏, 严福华.磁共振成像评估肝功能储备的研究进展[J].诊断学理论与实践, 2023, 22(2):190-196.
[6] 荐桂丽, 任玉环.血清HE4、CA125在子宫内膜癌中的研究[J].医学信息, 2021, 34(2):53-55.
[7] 李津健.CA125检测在卵巢癌诊疗中的研究进展[J].医学理论与实践, 2019, 32(11):1658-1659, 1662.
[8] 赵夏丰, 杨小华, 刘庆峰.血清CEA、CA125、AFP水平变化与肝脏疾病病情进展的关系[J].深圳中西医结合杂志, 2022, 32(6):30-32.
[9] 朱壹澎, 卢高峰, 黄丽娜, 等.血清CA125、CA199、CEA、AFP检测在肝炎与肝硬化鉴别诊断中的价值[J].山东医药, 2019, 59(1):46-48.
[10] 张潇, 王桂良, 李兴, 等.血清CA125在肝硬化腹腔积液患者治疗前后的变化及意义[J].中国现代医生, 2021, 59(34):8-11, 23, 193.
[11] 杨建波, 石睿, 马欢, 等.肝硬化患者血清前白蛋白、血清胆碱酯酶和总胆汁酸水平检测的临床意义[J].西部医学, 2022, 34(7):1006-1010.
[12] 翁丽燕.肝硬化患者血清PA、GGT、CHE表达水平与肝功能的相关性[J].现代诊断与治疗, 2021, 32(2):262-263.
[13] 郁沙莎, 潘波, 郭玉玉, 等.血清前白蛋白(PA)含量在肝脏TACE术患者预后中的临床价值[J].现代肿瘤医学, 2019, 27(2):278-280.
[14] 宋少娟, 苏国华.血清总胆汁酸、胆碱酯酶和前白蛋白检测在肝病诊断中应用探析[J].医学信息, 2021, 34(23):9-11.
[15] 薄涛, 黄华, 张保珍.血清CHE、PA和凝血四项在肝硬化Child-pugh分级中的临床应用[J].中国医药指南, 2015, 13(24):55-56.
[16] 董菁, 段雅洁.老年肝硬化患者血清胆碱酯酶血清白蛋白和凝血酶原时间变化及其与Child-Pugh分级的关系[J].河北医学, 2021, 27(12):1962-1965.
[17] 冯秀荣, 田华, 陈光福, 等.肝功能四项指标变化与肝炎肝硬化患者Child-Pugh分级的关联性[J].河南医学研究, 2021, 30(15):2857-2859.
[18] 吴佳雨, 张秉强.红细胞分布宽度在肝脏疾病中的应用进展[J].肝脏, 2021, 26(5):563-565.
[19] 向旭, 戴跃青.红细胞分布宽度与消化系统疾病关系的研究进展[J].胃肠病学和肝病学杂志, 2017, 26(7):812-815.
[20] 王晴晴, 丁洁, 武昆利, 等.基于MELD评分探讨RDW及ApoA1与肝硬化患者病情严重程度的关系[J].国际检验医学杂志, 2023, 44(18):2177-2181, 2186.
[21] 宋怡然, 张树荣.红细胞分布宽度与肝硬化Child-Pugh分级的相关性[J].海南医学, 2018, 29(9):1244-1246.
[22] 李韫池, 史也, 孙中磊, 等.RDW、血清OPN在肝硬化病程及Child-pugh分级中的应用[J].海南医学, 2020, 31(22):2884-2888.
[23] 刘忠敏.肝硬化患者血清胆碱酯酶和CA125联合检测的临床意义[J].中国卫生产业, 2014, 11(11):171-172.
[24] 黄祖雄.肝脏疾病诊断中血清前白蛋白、胆碱酯酶及总胆汁酸联合检测的价值[J].黑龙江医药, 2021, 34(1):216-218.
